For decades, the development of the next generations of drugs for neuropsychiatric symptoms has been one of the greatest challenges in neuroscience drug discovery.
In particular, the need to improve upon standard of care with respect to side effects or efficacy in treatment-resistant patient populations. We have seen a lot of novel molecular targets implicated and drugs clinically tested targeting depression, schizophrenia and neurodegenerative disease.